董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Birgit Girshick | 女 | Chief Executive Officer,Director,Executive Vice President and Chief Operating Officer | 56 | 589.84万美元 | 7.63 | 2026-05-05 |
| Mark Enyedy | 男 | Independent Director | 62 | 32.07万美元 | 0.30 | 2026-05-05 |
| Abraham Ceesay | 男 | Director | 48 | 32.07万美元 | 0.30 | 2026-05-05 |
| Virginia M. Wilson | 女 | Director | 71 | 34.59万美元 | 1.52 | 2026-05-05 |
| Nancy C. Andrews | 女 | Director | 67 | 34.09万美元 | 1.49 | 2026-05-05 |
| George Llado | 男 | Director | 60 | 32.59万美元 | 1.36 | 2026-05-05 |
| Steven Barg | 男 | Independent Director | 64 | 32.07万美元 | 0.35 | 2026-05-05 |
| Reshema Kemps Polanco | 女 | Director | 53 | 34.09万美元 | 0.64 | 2026-05-05 |
| Mark Enyedy | 男 | Independent Director | 62 | 未披露 | 未持股 | 2026-05-05 |
| Paul Graves | 男 | Independent Director | 55 | 34.57万美元 | 0.30 | 2026-05-05 |
| Martin W. Mackay | 男 | Director and Chair of the Board | 69 | 36.59万美元 | 2.46 | 2026-05-05 |
| James C. Foster | 男 | President and Non-Executive Director | 75 | 1543.52万美元 | 36.10 | 2026-05-05 |
| Craig B. Thompson | 男 | Director | 73 | 34.09万美元 | 0.81 | 2026-05-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Birgit Girshick | 女 | Chief Executive Officer,Director,Executive Vice President and Chief Operating Officer | 56 | 589.84万美元 | 7.63 | 2026-05-05 |
| Joseph LaPlume | 男 | Senior Corporate Counsel, Senior Vice President | 52 | 351.33万美元 | 2.82 | 2026-05-05 |
| Victoria Creamer | 女 | Executive Vice President | 56 | 333.24万美元 | 3.08 | 2026-05-05 |
| Shannon Parisotto | 女 | Executive Vice President | 52 | 未披露 | 未持股 | 2026-05-05 |
| Glenn Coleman | 男 | Chief Financial Officer and Corporate Executive Vice President | 58 | 未披露 | 未持股 | 2026-05-05 |
| James C. Foster | 男 | President and Non-Executive Director | 75 | 1543.52万美元 | 36.10 | 2026-05-05 |
| Michael G. Knell | 男 | Senior Vice President and Chief Accounting Officer, Chief Financial Officer | 49 | 210.77万美元 | 1.15 | 2026-05-05 |
董事简历
中英对照 | 中文 | 英文- Birgit Girshick
-
Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
Birgit Girshick joined Charles River Laboratories International, Inc. in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc.'s RMS Germany and Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc.'s then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc.'s Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities. Since 2023, Ms. Girshick also has general oversight of the Corporate Sales and Marketing team and Charles River Laboratories International, Inc.'s Corporate and External Affairs function. - Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
- Birgit Girshick joined Charles River Laboratories International, Inc. in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc.'s RMS Germany and Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc.'s then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc.'s Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities. Since 2023, Ms. Girshick also has general oversight of the Corporate Sales and Marketing team and Charles River Laboratories International, Inc.'s Corporate and External Affairs function.
- Mark Enyedy
-
Mark Enyedy，2013年以来，他一直任职Shire公司。他是公司开发主管，并于2015年1月1日被任命为临时总法律顾问。他也是Shire公司的执行委员会的成员。他此前曾担任Shire公司的内科业务单位主管（从2013年8月到2014年4月）。加入Shire公司之前，他曾担任Proteostasis Therapeutics公司的首席执行官。他也曾任职Genzyme Corporation公司，并在Palmer & Dodge公司从事法律执业。
Mark Enyedy,Mr. Enyedy has been with Shire since 2013. Mr. Enyedy is Head of Corporate Development and was appointed as Interim General Counsel on January 1 2015. Mr. Enyedy is also a member of Shire’s Executive Committee. Mr. Enyedy previously served as Shire’s Internal Medicine Business Unit Head from August 2013 until April 2014. Prior to joining Shire Mr. Enyedy was Chief Executive Officer at Proteostasis Therapeutics, Inc.. Mr. Enyedy also held positions with Genzyme Corporation and practiced law at the firm Palmer & Dodge. - Mark Enyedy，2013年以来，他一直任职Shire公司。他是公司开发主管，并于2015年1月1日被任命为临时总法律顾问。他也是Shire公司的执行委员会的成员。他此前曾担任Shire公司的内科业务单位主管（从2013年8月到2014年4月）。加入Shire公司之前，他曾担任Proteostasis Therapeutics公司的首席执行官。他也曾任职Genzyme Corporation公司，并在Palmer & Dodge公司从事法律执业。
- Mark Enyedy,Mr. Enyedy has been with Shire since 2013. Mr. Enyedy is Head of Corporate Development and was appointed as Interim General Counsel on January 1 2015. Mr. Enyedy is also a member of Shire’s Executive Committee. Mr. Enyedy previously served as Shire’s Internal Medicine Business Unit Head from August 2013 until April 2014. Prior to joining Shire Mr. Enyedy was Chief Executive Officer at Proteostasis Therapeutics, Inc.. Mr. Enyedy also held positions with Genzyme Corporation and practiced law at the firm Palmer & Dodge.
- Abraham Ceesay
-
Abraham Ceesay于2016年3月加入我们公司，担任首席运营官。在此之前，Ceesay从2014年到2016年担任Keryx Biopharmaceuticals（一家专注于肾脏疾病的生物制药公司）Vice President、销售、营销和商业运营。在加入Keryx之前，Ceesay先生曾于2010年至2014年在药品制造商Ironwood Pharmaceuticals担任市场营销Vice President。此前，Ceesay从2002年到2010年在Genzyme/Sanofi（一家生物技术公司）任职，最初担任现场销售专员，最终担任Renal Global Marketing主管。Ceesay先生拥有伊萨卡学院（Ithaca College）的健康教育与生理学学士学位，以及萨福克大学（Suffolk University）索耶管理学院（Sawyer School of Management）的工商管理硕士学位。
Abraham Ceesay served as Vice President, Sales, Marketing, and Commercial Operations at Keryx Biopharmaceuticals, a biopharmaceutical company focused on renal disease, from 2014 to 2016. Prior to his career at Keryx, Mr. Ceesay served at Ironwood Pharmaceuticals, a drug manufacturer, as vice president, Marketing, from 2010 to 2014. Prior to that, from 2002 to 2010 Mr. Ceesay served at Genzyme/Sanofi, a biotechnology company, initially as a field sales specialist and ultimately as the Director, Renal Global Marketing. Mr. Ceesay holds a B.S. in Health Education & Physiology from Ithaca College, and an M.B.A. from Suffolk University's Sawyer School of Management. - Abraham Ceesay于2016年3月加入我们公司，担任首席运营官。在此之前，Ceesay从2014年到2016年担任Keryx Biopharmaceuticals（一家专注于肾脏疾病的生物制药公司）Vice President、销售、营销和商业运营。在加入Keryx之前，Ceesay先生曾于2010年至2014年在药品制造商Ironwood Pharmaceuticals担任市场营销Vice President。此前，Ceesay从2002年到2010年在Genzyme/Sanofi（一家生物技术公司）任职，最初担任现场销售专员，最终担任Renal Global Marketing主管。Ceesay先生拥有伊萨卡学院（Ithaca College）的健康教育与生理学学士学位，以及萨福克大学（Suffolk University）索耶管理学院（Sawyer School of Management）的工商管理硕士学位。
- Abraham Ceesay served as Vice President, Sales, Marketing, and Commercial Operations at Keryx Biopharmaceuticals, a biopharmaceutical company focused on renal disease, from 2014 to 2016. Prior to his career at Keryx, Mr. Ceesay served at Ironwood Pharmaceuticals, a drug manufacturer, as vice president, Marketing, from 2010 to 2014. Prior to that, from 2002 to 2010 Mr. Ceesay served at Genzyme/Sanofi, a biotechnology company, initially as a field sales specialist and ultimately as the Director, Renal Global Marketing. Mr. Ceesay holds a B.S. in Health Education & Physiology from Ithaca College, and an M.B.A. from Suffolk University's Sawyer School of Management.
- Virginia M. Wilson
-
Virginia M. Wilson，TIAA退休的高级执行副总裁兼首席财务官，负责领导财务和精算职能。在2010年加入TIAA之前，Wilson女士曾担任Wyndham Worldwide Corporation执行副总裁兼首席财务官，在Wyndham于2006年从Cendant Corporation分拆后领导其财务和技术组织。此前，她曾担任Cendant的执行副总裁兼首席会计官，还曾担任大都会人寿公司和Transamerica人寿保险部门的高级副总裁兼公司财务总监。Wilson女士的职业生涯始于德勤，是一名注册会计师。她是Carrier Global Corporation现任董事会成员和Conduent Incorporated前任董事会成员。Wilson女士自2019年10月起担任董事。Wilson女士为董事会带来了30多年的财务管理经验，负责监督大型跨国组织的会计、精算、税务以及财务规划和报告职能。此外，由于她的注册会计师背景和之前担任过上市公司首席财务官的服务，Wilson女士有资格成为SEC准则下的“审计委员会财务专家”。
Virginia M. Wilson served as Executive Vice President and Chief Financial Officer of Wyndham Worldwide Corporation, leading Wyndham's finance and technology organizations following its spin off from Cendant Corporation in 2006. Previously, she served as Cendant's Executive Vice President and Chief Accounting Officer and also served as Senior Vice President and Corporate Controller of both MetLife, Inc. and Transamerica's life insurance division. Ms. Wilson began her career at Deloitte and is a Certified Public Accountant. She is a current member of the board of directors of Carrier Global Corporation and a former member of the board of directors of Conduent Incorporated. Ms. Wilson has been a director since October 2019. - Virginia M. Wilson，TIAA退休的高级执行副总裁兼首席财务官，负责领导财务和精算职能。在2010年加入TIAA之前，Wilson女士曾担任Wyndham Worldwide Corporation执行副总裁兼首席财务官，在Wyndham于2006年从Cendant Corporation分拆后领导其财务和技术组织。此前，她曾担任Cendant的执行副总裁兼首席会计官，还曾担任大都会人寿公司和Transamerica人寿保险部门的高级副总裁兼公司财务总监。Wilson女士的职业生涯始于德勤，是一名注册会计师。她是Carrier Global Corporation现任董事会成员和Conduent Incorporated前任董事会成员。Wilson女士自2019年10月起担任董事。Wilson女士为董事会带来了30多年的财务管理经验，负责监督大型跨国组织的会计、精算、税务以及财务规划和报告职能。此外，由于她的注册会计师背景和之前担任过上市公司首席财务官的服务，Wilson女士有资格成为SEC准则下的“审计委员会财务专家”。
- Virginia M. Wilson served as Executive Vice President and Chief Financial Officer of Wyndham Worldwide Corporation, leading Wyndham's finance and technology organizations following its spin off from Cendant Corporation in 2006. Previously, she served as Cendant's Executive Vice President and Chief Accounting Officer and also served as Senior Vice President and Corporate Controller of both MetLife, Inc. and Transamerica's life insurance division. Ms. Wilson began her career at Deloitte and is a Certified Public Accountant. She is a current member of the board of directors of Carrier Global Corporation and a former member of the board of directors of Conduent Incorporated. Ms. Wilson has been a director since October 2019.
- Nancy C. Andrews
-
Nancy C. Andrews，杜克大学儿科教授、药理学和癌症生物学教授（2007年以来），2013年至2020年纳纳琳·h·杜克捐赠的主席。从2007年到2017年，Andrews博士担任杜克大学医学院院长和杜克大学学术事务副校长。从2003年到2007年，她担任哈佛大学医学院（Harvard University Medical School）基础科学和研究生研究主任和儿科教授。从1999年到2003年，她担任哈佛-麻省理工学院（Harvard-Massachusetts Institute of Technology）主任。项目，以及其MSTP赠款的主要研究者。从1993年到2006年，她是霍华德休斯医学研究所的生物医学研究员。她是MIT公司的执行委员会成员，美国艺术与科学学院的董事会主席，以及Dyne Therapeutics的科学顾问委员会成员。她是the National Academy of Medicine和the National Academy of Sciences的当选成员，目前任职于the National Academy of Sciences的理事会。她是Burroughs Wellcome Fund的前董事会主席，也是National Institutes of Health的科学管理审查委员会的前成员。她还担任Novartis International AG和Maze Therapeutics的董事会成员。Andrews博士自2020年2月起担任Charles River Laboratories International, Inc.的董事会成员。
Nancy C. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University. From 2003 to 2007, she served as Dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a biomedical research investigator of the Howard Hughes Medical Institute. She is a member of the Scientific Advisory Boards of Dyne Therapeutics (since 2018) and Cajal Therapeutics (since January 2026). She is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine and the National Academy of Sciences, and currently serves as Home Secretary for the National Academy of Sciences. Dr. Andrews previously served as Chair of the Boards of Directors of the American Academy of Arts and Sciences and the Burroughs Wellcome Fund. She is a former member of the Scientific Management Review Board at the National Institutes of Health. Dr. Andrews also serves on the boards of directors of Novartis International AG and Maze Therapeutics and on the MIT Corporation, MIT's board of trustees. Dr. Andrews has been a director since February 2020. - Nancy C. Andrews，杜克大学儿科教授、药理学和癌症生物学教授（2007年以来），2013年至2020年纳纳琳·h·杜克捐赠的主席。从2007年到2017年，Andrews博士担任杜克大学医学院院长和杜克大学学术事务副校长。从2003年到2007年，她担任哈佛大学医学院（Harvard University Medical School）基础科学和研究生研究主任和儿科教授。从1999年到2003年，她担任哈佛-麻省理工学院（Harvard-Massachusetts Institute of Technology）主任。项目，以及其MSTP赠款的主要研究者。从1993年到2006年，她是霍华德休斯医学研究所的生物医学研究员。她是MIT公司的执行委员会成员，美国艺术与科学学院的董事会主席，以及Dyne Therapeutics的科学顾问委员会成员。她是the National Academy of Medicine和the National Academy of Sciences的当选成员，目前任职于the National Academy of Sciences的理事会。她是Burroughs Wellcome Fund的前董事会主席，也是National Institutes of Health的科学管理审查委员会的前成员。她还担任Novartis International AG和Maze Therapeutics的董事会成员。Andrews博士自2020年2月起担任Charles River Laboratories International, Inc.的董事会成员。
- Nancy C. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University. From 2003 to 2007, she served as Dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a biomedical research investigator of the Howard Hughes Medical Institute. She is a member of the Scientific Advisory Boards of Dyne Therapeutics (since 2018) and Cajal Therapeutics (since January 2026). She is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine and the National Academy of Sciences, and currently serves as Home Secretary for the National Academy of Sciences. Dr. Andrews previously served as Chair of the Boards of Directors of the American Academy of Arts and Sciences and the Burroughs Wellcome Fund. She is a former member of the Scientific Management Review Board at the National Institutes of Health. Dr. Andrews also serves on the boards of directors of Novartis International AG and Maze Therapeutics and on the MIT Corporation, MIT's board of trustees. Dr. Andrews has been a director since February 2020.
- George Llado
-
George Llado，自2015年起担任Alexion Pharmaceuticals, Inc.的高级副总裁兼首席信息官。作为一个拥有超过30年制药业务、技术和网络安全经验的行业资深人士，Llado先生和他在Alexion的全球团队开发和实施创新技术，并使数据驱动的洞察力贯穿Alexion的研发、商业、制造运营和供应链职能。加入Alexion之前，Llado先生担任Merck and Co.的副总裁和业务线CIO，在那里他领导公司制造部门的IT解决方案的规划和开发。在此之前，他是默克公司的副总裁，负责全球商业组织和各种企业一般与行政职能的IT和业务线CIO。他领导了默克和先灵葆雅跨IT和共享业务服务组织的大规模合并整合。他还在默克公司担任多个其他职位，并在花旗银行（Citibank, N.A。）工作。他任职于国家妇女与信息技术中心（NCWIT）董事会，他是董事会发展委员会的成员，并赞助了“计算机顾问”等重要项目，这些项目提高了该组织的会员资格。他还任职于Temple Fox Business School IT顾问委员会。Llado先生自2020年10月起担任董事。
George Llado served as Vice President and business line CIO for Merck and Co., where he led the planning and development of IT solutions for the company's Manufacturing Division. Before that, he was Merck's Vice President, IT and business line CIO for the Global Commercial Organization and various corporate G&A functions. He led the large scale merger integration of Merck and Schering Plough across the IT and Shared Business Services organizations. He also held several other positions of increasing responsibility at Merck, and previously worked at Citibank, N.A. Mr. Llado serves on the TraceLink Inc. and National Center for Women & Information Technology (NCWIT) Board. Mr. Llado has been a director since October 2020. - George Llado，自2015年起担任Alexion Pharmaceuticals, Inc.的高级副总裁兼首席信息官。作为一个拥有超过30年制药业务、技术和网络安全经验的行业资深人士，Llado先生和他在Alexion的全球团队开发和实施创新技术，并使数据驱动的洞察力贯穿Alexion的研发、商业、制造运营和供应链职能。加入Alexion之前，Llado先生担任Merck and Co.的副总裁和业务线CIO，在那里他领导公司制造部门的IT解决方案的规划和开发。在此之前，他是默克公司的副总裁，负责全球商业组织和各种企业一般与行政职能的IT和业务线CIO。他领导了默克和先灵葆雅跨IT和共享业务服务组织的大规模合并整合。他还在默克公司担任多个其他职位，并在花旗银行（Citibank, N.A。）工作。他任职于国家妇女与信息技术中心（NCWIT）董事会，他是董事会发展委员会的成员，并赞助了“计算机顾问”等重要项目，这些项目提高了该组织的会员资格。他还任职于Temple Fox Business School IT顾问委员会。Llado先生自2020年10月起担任董事。
- George Llado served as Vice President and business line CIO for Merck and Co., where he led the planning and development of IT solutions for the company's Manufacturing Division. Before that, he was Merck's Vice President, IT and business line CIO for the Global Commercial Organization and various corporate G&A functions. He led the large scale merger integration of Merck and Schering Plough across the IT and Shared Business Services organizations. He also held several other positions of increasing responsibility at Merck, and previously worked at Citibank, N.A. Mr. Llado serves on the TraceLink Inc. and National Center for Women & Information Technology (NCWIT) Board. Mr. Llado has been a director since October 2020.
- Steven Barg
-
Steven Barg自2021年2月起担任Elliott Opportunity II Corp.的首席财务官，Elliott Opportunity II Corp.是一家特殊目的收购公司，由EIM的关联公司赞助。他是Elliott Investment Management L.P.的企业参与全球主管。在2020年2月加入Elliott之前，Barg先生曾在2010年至2019年期间担任高盛的董事总经理。从2010年到2012年，Barg先生担任香港亚洲股票资本市场联席主管。2013年，他回到纽约，创立了公司的行动主义和股东咨询业务，并在全球范围内一直领导到2019年。此外，在高盛任职期间，Barg先生曾在亚洲和全球股票承诺委员会任职，并担任投资银行司的全球多元化主管。在加入高盛之前，Barg先生于2006年开始在香港经营UBS的亚洲股票业务和综合资本市场业务。在加入UBS之前，巴格还曾在纽约和伦敦的瑞士信贷银行担任股票资本市场董事总经理。在加入Elliott之前，Barg先生总共有30年的投资银行生涯。Barg先生拥有卫斯理大学的学士学位和斯坦福大学商学院的工商管理硕士学位。此外，Barg先生是香港的Henry Luce学者和纽约的Coro公共事务研究员。
Steven Barg,has been a member of the Board since September 2023. Mr. Barg is Global Head of Engagement at Elliott. Prior to joining Elliott in February 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs. During his time at Goldman Sachs, Mr. Barg established and led what became the firm's Global Activism and Shareholder Advisory practice; founded and led the M&A Capital Markets practice; and ran Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both the Asian and Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Prior to joining Goldman Sachs, Mr. Barg served as a Managing Director in Equity Capital Markets at UBS and Credit Suisse, with postings in New York, Hong Kong, and London. Mr. Barg has served on the Board of Directors of Cardinal Health since September 2022. Mr. Barg holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg was a Henry Luce Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York. - Steven Barg自2021年2月起担任Elliott Opportunity II Corp.的首席财务官，Elliott Opportunity II Corp.是一家特殊目的收购公司，由EIM的关联公司赞助。他是Elliott Investment Management L.P.的企业参与全球主管。在2020年2月加入Elliott之前，Barg先生曾在2010年至2019年期间担任高盛的董事总经理。从2010年到2012年，Barg先生担任香港亚洲股票资本市场联席主管。2013年，他回到纽约，创立了公司的行动主义和股东咨询业务，并在全球范围内一直领导到2019年。此外，在高盛任职期间，Barg先生曾在亚洲和全球股票承诺委员会任职，并担任投资银行司的全球多元化主管。在加入高盛之前，Barg先生于2006年开始在香港经营UBS的亚洲股票业务和综合资本市场业务。在加入UBS之前，巴格还曾在纽约和伦敦的瑞士信贷银行担任股票资本市场董事总经理。在加入Elliott之前，Barg先生总共有30年的投资银行生涯。Barg先生拥有卫斯理大学的学士学位和斯坦福大学商学院的工商管理硕士学位。此外，Barg先生是香港的Henry Luce学者和纽约的Coro公共事务研究员。
- Steven Barg,has been a member of the Board since September 2023. Mr. Barg is Global Head of Engagement at Elliott. Prior to joining Elliott in February 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs. During his time at Goldman Sachs, Mr. Barg established and led what became the firm's Global Activism and Shareholder Advisory practice; founded and led the M&A Capital Markets practice; and ran Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both the Asian and Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Prior to joining Goldman Sachs, Mr. Barg served as a Managing Director in Equity Capital Markets at UBS and Credit Suisse, with postings in New York, Hong Kong, and London. Mr. Barg has served on the Board of Directors of Cardinal Health since September 2022. Mr. Barg holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg was a Henry Luce Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York.
- Reshema Kemps Polanco
-
Reshema Kemps Polanco，拥有25年的制药行业经验，目前担任Novartis US（全球生物制药公司Novartis AG的美国业务）的执行副总裁兼首席商务官。在此职位上，她负责四个治疗领域的端到端商业化，包括肿瘤学、免疫学、神经病学和心血管/肾脏/代谢疾病。在2021年重新加入Novartis之前，Kemps-Polanco女士从2014年到2021年在Johnson & Johnson担任多个领导职务，最近担任Janssen U.S. Cardiovascular & Metabolism和Janssen Pharmaceuticals Puerto Rico的总裁。在此职位上，她负责开发和交付业务战略，并推动这些业务的增长计划。
Reshema Kemps Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company Novartis AG, responsible for end to end commercialization across four therapeutic areas. Ms. Kemps Polanco returned to Novartis in 2021 as EVP & US Head, Novartis Oncology. Prior to rejoining Novartis, Ms. Kemps Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Ms. Kemps Polanco began her pharmaceutical industry career at Novartis in 2012 in sales and held management positions of increasing responsibility. Ms. Kemps Polanco is a member of the Rutgers Cancer Institute Leadership Council, the Healthcare Businesswomen's Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps Polanco has been a board member since January 2024. - Reshema Kemps Polanco，拥有25年的制药行业经验，目前担任Novartis US（全球生物制药公司Novartis AG的美国业务）的执行副总裁兼首席商务官。在此职位上，她负责四个治疗领域的端到端商业化，包括肿瘤学、免疫学、神经病学和心血管/肾脏/代谢疾病。在2021年重新加入Novartis之前，Kemps-Polanco女士从2014年到2021年在Johnson & Johnson担任多个领导职务，最近担任Janssen U.S. Cardiovascular & Metabolism和Janssen Pharmaceuticals Puerto Rico的总裁。在此职位上，她负责开发和交付业务战略，并推动这些业务的增长计划。
- Reshema Kemps Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company Novartis AG, responsible for end to end commercialization across four therapeutic areas. Ms. Kemps Polanco returned to Novartis in 2021 as EVP & US Head, Novartis Oncology. Prior to rejoining Novartis, Ms. Kemps Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Ms. Kemps Polanco began her pharmaceutical industry career at Novartis in 2012 in sales and held management positions of increasing responsibility. Ms. Kemps Polanco is a member of the Rutgers Cancer Institute Leadership Council, the Healthcare Businesswomen's Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps Polanco has been a board member since January 2024.
- Mark Enyedy
-
Mark Enyedy从Shire PLC加入ImmunoGen，曾担任执行副总裁兼企业发展主管，领导公司的战略、并购和企业规划职能，并为公司的第3阶段前投资组合提供商业监督。在此之前，Enyedy先生曾担任Proteostasis Therapeutics的首席执行官和董事，此前在健赞工作了15年，担任过多种职务，最近担任移植、肿瘤学和多发性硬化症部门的总裁。在加入Genzyme之前，Enyedy先生是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy先生目前在Astellas Pharma、BioMarin和Ergomed plc的董事会任职，此前曾在ImmunoGen、LogicBio医疗 Bio Therapeutics、Akebia Therapeutics、Fate Therapeutics、克律克斯生物制药的董事会任职。他还曾在美国东部新英格兰癌症协会和生物技术创新组织的董事会任职。Enyedy先生自2025年5月起担任董事。
Mark Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company's strategy, M&A, and corporate planning functions and providing commercial oversight for the company's pre Phase 3 portfolio. Previously, Mr. Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge. Mr. Enyedy currently serves on the boards of Astellas Pharma, BioMarin and Ergomed plc, and previously served on the boards of ImmunoGen, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals. He also served on the boards of The American Cancer Society of Eastern New England and The Biotechnology Innovation Organization. Mr. Enyedy has been a director since May 2025. - Mark Enyedy从Shire PLC加入ImmunoGen，曾担任执行副总裁兼企业发展主管，领导公司的战略、并购和企业规划职能，并为公司的第3阶段前投资组合提供商业监督。在此之前，Enyedy先生曾担任Proteostasis Therapeutics的首席执行官和董事，此前在健赞工作了15年，担任过多种职务，最近担任移植、肿瘤学和多发性硬化症部门的总裁。在加入Genzyme之前，Enyedy先生是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy先生目前在Astellas Pharma、BioMarin和Ergomed plc的董事会任职，此前曾在ImmunoGen、LogicBio医疗 Bio Therapeutics、Akebia Therapeutics、Fate Therapeutics、克律克斯生物制药的董事会任职。他还曾在美国东部新英格兰癌症协会和生物技术创新组织的董事会任职。Enyedy先生自2025年5月起担任董事。
- Mark Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company's strategy, M&A, and corporate planning functions and providing commercial oversight for the company's pre Phase 3 portfolio. Previously, Mr. Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge. Mr. Enyedy currently serves on the boards of Astellas Pharma, BioMarin and Ergomed plc, and previously served on the boards of ImmunoGen, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals. He also served on the boards of The American Cancer Society of Eastern New England and The Biotechnology Innovation Organization. Mr. Enyedy has been a director since May 2025.
- Paul Graves
-
Paul Graves曾担任Livent Corporation的首席执行官，并且是与Allkem Limited合并过程中不可分割的一部分，后者创建了Arcadium Lithium。在此之前，Graves先生是FMC公司的执行副总裁兼首席财务官。在加入FMC之前，他是高盛 Sachs的合伙人，担任过多种职务，包括亚洲自然资源主管和化学品投资银行业务全球主管。Graves先生曾在Arcadium Lithium的董事会任职，直至其被力拓收购，此前还曾在Livent和Lydall, Inc.的董事会任职。Graves先生自2025年5月起担任董事。
Paul Graves served as Chief Executive Officer of Livent Corporation and was an integral part of the merger with Allkem Limited that created Arcadium Lithium. Previously, Mr. Graves was the Executive Vice President and Chief Financial Officer of FMC Corporation. Before joining FMC, he was a partner at Goldman Sachs, serving in a variety of roles, including as Head of Natural Resources for Asia and Global Head of Chemical Investment Banking. Mr. Graves served on the board of Arcadium Lithium until its acquisition by Rio Tinto, and also previously served on the boards of Livent and Lydall, Inc. Mr. Graves has been a director since May 2025. - Paul Graves曾担任Livent Corporation的首席执行官，并且是与Allkem Limited合并过程中不可分割的一部分，后者创建了Arcadium Lithium。在此之前，Graves先生是FMC公司的执行副总裁兼首席财务官。在加入FMC之前，他是高盛 Sachs的合伙人，担任过多种职务，包括亚洲自然资源主管和化学品投资银行业务全球主管。Graves先生曾在Arcadium Lithium的董事会任职，直至其被力拓收购，此前还曾在Livent和Lydall, Inc.的董事会任职。Graves先生自2025年5月起担任董事。
- Paul Graves served as Chief Executive Officer of Livent Corporation and was an integral part of the merger with Allkem Limited that created Arcadium Lithium. Previously, Mr. Graves was the Executive Vice President and Chief Financial Officer of FMC Corporation. Before joining FMC, he was a partner at Goldman Sachs, serving in a variety of roles, including as Head of Natural Resources for Asia and Global Head of Chemical Investment Banking. Mr. Graves served on the board of Arcadium Lithium until its acquisition by Rio Tinto, and also previously served on the boards of Livent and Lydall, Inc. Mr. Graves has been a director since May 2025.
- Martin W. Mackay
-
Martin W. Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
Martin W. Mackay is a co founder of Rallybio and Chairman of Rallybio's Board. From January 2018 until August 2023, Dr. Mackay served as Chief Executive Officer and Chairman of the Board of Directors of Rallybio, and from August 2023 until December 2024 he served as Executive Chairman. From March 2013 to December 2017, Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013, Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of Charles River Laboratories International, Inc. and Sail Biomedicines. He previously served as a director of 5AM Acquisition Co. from October 2020 until April 2022. Dr. Mackay served on the board of Novo Nordisk from 2018 through 2025, and on the board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. Dr. Mackay received a BSc First Class in microbiology from Heriot Watt University and a Ph.D. in molecular genetics from the University of Edinburgh. - Martin W. Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
- Martin W. Mackay is a co founder of Rallybio and Chairman of Rallybio's Board. From January 2018 until August 2023, Dr. Mackay served as Chief Executive Officer and Chairman of the Board of Directors of Rallybio, and from August 2023 until December 2024 he served as Executive Chairman. From March 2013 to December 2017, Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013, Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of Charles River Laboratories International, Inc. and Sail Biomedicines. He previously served as a director of 5AM Acquisition Co. from October 2020 until April 2022. Dr. Mackay served on the board of Novo Nordisk from 2018 through 2025, and on the board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. Dr. Mackay received a BSc First Class in microbiology from Heriot Watt University and a Ph.D. in molecular genetics from the University of Edinburgh.
- James C. Foster
-
James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
James C. Foster joined Charles River Laboratories International, Inc. in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989. - James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
- James C. Foster joined Charles River Laboratories International, Inc. in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.
- Craig B. Thompson
-
Craig B. Thompson， 2010年11月起，他担任Memorial Sloan-Kettering Cancer Center的总裁和首席行政官；2006年至2010年，他担任宾夕法尼亚大学医学院Abramson Cancer Center的董事；1999年至2011年，他担任宾夕法尼亚大学医疗和癌症学教授。他是American Academy of Arts and Sciences研究员、Howard Hughes Medical Institute医学顾问委员会、National Academy of Sciences以及National Academy of Sciences的医学协会成员。他是Merck & Co的董事。2013年起，他成为董事。
Craig B. Thompson continues to oversee a research laboratory at the Sloan Kettering Institute focusing on cellular metabolism and its role in cancer. From 2006 to 2010, Dr. Thompson served as the Director of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, and, from 1999 to 2011, he was a Professor of Medicine and Cancer Biology at the University of Pennsylvania. Dr. Thompson is currently a member of the Board of Directors of Regeneron Pharmaceuticals, Inc., and he previously served on the Board of Directors of Merck & Co. Inc. from 2009 to 2018. He is also a board member of the Howard Hughes Medical Institute, M.D. Anderson Cancer Center, Ohio State University Comprehensive Cancer Center, and a member of the Albert Lasker Medical Research Awards Prize Committee. Dr. Thompson is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Association of American Physicians. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis and has founded three biotechnology companies, including Agios Pharmaceuticals. Dr. Thompson has been a director since December 2022. - Craig B. Thompson， 2010年11月起，他担任Memorial Sloan-Kettering Cancer Center的总裁和首席行政官；2006年至2010年，他担任宾夕法尼亚大学医学院Abramson Cancer Center的董事；1999年至2011年，他担任宾夕法尼亚大学医疗和癌症学教授。他是American Academy of Arts and Sciences研究员、Howard Hughes Medical Institute医学顾问委员会、National Academy of Sciences以及National Academy of Sciences的医学协会成员。他是Merck & Co的董事。2013年起，他成为董事。
- Craig B. Thompson continues to oversee a research laboratory at the Sloan Kettering Institute focusing on cellular metabolism and its role in cancer. From 2006 to 2010, Dr. Thompson served as the Director of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, and, from 1999 to 2011, he was a Professor of Medicine and Cancer Biology at the University of Pennsylvania. Dr. Thompson is currently a member of the Board of Directors of Regeneron Pharmaceuticals, Inc., and he previously served on the Board of Directors of Merck & Co. Inc. from 2009 to 2018. He is also a board member of the Howard Hughes Medical Institute, M.D. Anderson Cancer Center, Ohio State University Comprehensive Cancer Center, and a member of the Albert Lasker Medical Research Awards Prize Committee. Dr. Thompson is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Association of American Physicians. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis and has founded three biotechnology companies, including Agios Pharmaceuticals. Dr. Thompson has been a director since December 2022.
高管简历
中英对照 | 中文 | 英文- Birgit Girshick
Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
Birgit Girshick joined Charles River Laboratories International, Inc. in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc.'s RMS Germany and Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc.'s then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc.'s Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities. Since 2023, Ms. Girshick also has general oversight of the Corporate Sales and Marketing team and Charles River Laboratories International, Inc.'s Corporate and External Affairs function.- Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
- Birgit Girshick joined Charles River Laboratories International, Inc. in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc.'s RMS Germany and Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc.'s then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc.'s Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities. Since 2023, Ms. Girshick also has general oversight of the Corporate Sales and Marketing team and Charles River Laboratories International, Inc.'s Corporate and External Affairs function.
- Joseph LaPlume
Joseph LaPlume，2005年加入Charles River Laboratories International，Inc.，担任高级公司法律顾问。他于2010年成为副总法律顾问，2011年成为公司发展副总裁，2014年成为高级副总裁，2019年1月成为发展和战略执行副总裁。在目前的职位上，他负责监督跨业务部门和地域的战略规划和公司发展活动的各个方面。在加入Charles River Laboratories International, Inc.之前，LaPlume先生是GTECH公司的公司律师，并在Mintz Levin和Goulston & Storrs律师事务所从事私人执业。
Joseph LaPlume joined in 2005 as Senior Corporate Counsel. He became Deputy General Counsel in 2010, Vice President, Corporate Development in 2011, Senior Vice President in 2014 and Corporate Executive Vice President, Corporate Development and Strategy in January 2019. In his current role, he oversees all aspects of strategic planning and corporate development activities across biness segments and geographies. Prior to joining , Mr. LaPlume was a corporate lawyer at GTECH Corporation and in private practice at the law firms of Mintz Levin and Goulston & Storrs.- Joseph LaPlume，2005年加入Charles River Laboratories International，Inc.，担任高级公司法律顾问。他于2010年成为副总法律顾问，2011年成为公司发展副总裁，2014年成为高级副总裁，2019年1月成为发展和战略执行副总裁。在目前的职位上，他负责监督跨业务部门和地域的战略规划和公司发展活动的各个方面。在加入Charles River Laboratories International, Inc.之前，LaPlume先生是GTECH公司的公司律师，并在Mintz Levin和Goulston & Storrs律师事务所从事私人执业。
- Joseph LaPlume joined in 2005 as Senior Corporate Counsel. He became Deputy General Counsel in 2010, Vice President, Corporate Development in 2011, Senior Vice President in 2014 and Corporate Executive Vice President, Corporate Development and Strategy in January 2019. In his current role, he oversees all aspects of strategic planning and corporate development activities across biness segments and geographies. Prior to joining , Mr. LaPlume was a corporate lawyer at GTECH Corporation and in private practice at the law firms of Mintz Levin and Goulston & Storrs.
- Victoria Creamer
Victoria Creamer于2019年加入Charles River Laboratories International, Inc.，担任高级副总裁兼首席人力资源官。2020年，Creamer女士晋升为公司执行副总裁。加入公司之前，Creamer女士在ITT和IBM各担任高级管理人力资源职位。
Victoria Creamer joined in January 2019 as Senior Vice President, Chief People Officer. In October 2020, Ms. Creamer was promoted to Corporate Executive Vice President. Prior to joining the Company, from 2015 to December 2018, Ms. Creamer served as Senior Vice President, Human Resces and Communications for ITT, Inc., a manufacturing company, where she was responsible for providing vision, leadership and execution of the company's people and communications strategies.- Victoria Creamer于2019年加入Charles River Laboratories International, Inc.，担任高级副总裁兼首席人力资源官。2020年，Creamer女士晋升为公司执行副总裁。加入公司之前，Creamer女士在ITT和IBM各担任高级管理人力资源职位。
- Victoria Creamer joined in January 2019 as Senior Vice President, Chief People Officer. In October 2020, Ms. Creamer was promoted to Corporate Executive Vice President. Prior to joining the Company, from 2015 to December 2018, Ms. Creamer served as Senior Vice President, Human Resces and Communications for ITT, Inc., a manufacturing company, where she was responsible for providing vision, leadership and execution of the company's people and communications strategies.
- Shannon Parisotto
Shannon Parisotto托于2000年加入Charles River Laboratories International，Inc.，参与内华达州股份有限公司的Charles River实验室国际业务。Parisotto女士通过了一系列责任越来越大的财务管理职位，并于2010年晋升为财务部临床前服务公司副总裁。在这一职位上，Parisotto女士负责全球临床前服务业务的财务运营。从2011年开始，Parisotto女士的角色扩大到包括其他业务部门，2015年，她晋升为新设立的全球运营公司高级副总裁兼财务总监，在那里她与Charles River的业务部门合作制定和实施业务战略。2020年，Parisotto女士晋升为全球安全评估公司高级副总裁，负责领导公司的全球安全评估组织，并将业务定位为持续、长期增长和成功。2022年10月，Parisotto女士晋升为公司执行副总裁，并承担了对发现服务业务的额外监督，以领导其战略愿景和运营增长，并加强业务之间以及与全球发现和安全评估部门客户之间的协同作用。Parisotto女士拥有内华达大学雷诺分校会计学学士学位，凤凰大学工商管理硕士学位，是一名注册会计师。
Shannon Parisotto joined in 2000 in Nevada operation. Ms. Parisotto progressed through a number of finance management positions of increasing responsibility, and in 2010, was promoted to Corporate Vice President, Preclinical Services, Finance. In this role, Ms. Parisotto was responsible for the financial operations of the global Preclinical Services biness. Beginning in 2011, Ms. Parisotto's role was expanded to include additional biness segments, and in 2015, she was promoted to the newly created position of Corporate Senior Vice President & Controller, Global Operations, where she worked collaboratively with Charles River's biness units to develop and implement biness strategies. In 2020, Ms. Parisotto was promoted to Corporate Senior Vice President, Global Safety Assessment, where she was responsible for leading the Company's global Safety Assessment organization, and positioning the biness for continued, long term growth and success. In October 2022, Ms. Parisotto was promoted to Corporate Executive Vice President, and assumed the additional oversight of then Discovery Services biness to lead its strategic vision and operational growth, as ll as enhance the synergies beten the binesses and with clients across the global DSA segment. Ms. Parisotto holds a B.S. in Accounting from the University of Nevada, Reno, an M.B.A. from the University of Phoenix, and is a Certified Public Accountant.- Shannon Parisotto托于2000年加入Charles River Laboratories International，Inc.，参与内华达州股份有限公司的Charles River实验室国际业务。Parisotto女士通过了一系列责任越来越大的财务管理职位，并于2010年晋升为财务部临床前服务公司副总裁。在这一职位上，Parisotto女士负责全球临床前服务业务的财务运营。从2011年开始，Parisotto女士的角色扩大到包括其他业务部门，2015年，她晋升为新设立的全球运营公司高级副总裁兼财务总监，在那里她与Charles River的业务部门合作制定和实施业务战略。2020年，Parisotto女士晋升为全球安全评估公司高级副总裁，负责领导公司的全球安全评估组织，并将业务定位为持续、长期增长和成功。2022年10月，Parisotto女士晋升为公司执行副总裁，并承担了对发现服务业务的额外监督，以领导其战略愿景和运营增长，并加强业务之间以及与全球发现和安全评估部门客户之间的协同作用。Parisotto女士拥有内华达大学雷诺分校会计学学士学位，凤凰大学工商管理硕士学位，是一名注册会计师。
- Shannon Parisotto joined in 2000 in Nevada operation. Ms. Parisotto progressed through a number of finance management positions of increasing responsibility, and in 2010, was promoted to Corporate Vice President, Preclinical Services, Finance. In this role, Ms. Parisotto was responsible for the financial operations of the global Preclinical Services biness. Beginning in 2011, Ms. Parisotto's role was expanded to include additional biness segments, and in 2015, she was promoted to the newly created position of Corporate Senior Vice President & Controller, Global Operations, where she worked collaboratively with Charles River's biness units to develop and implement biness strategies. In 2020, Ms. Parisotto was promoted to Corporate Senior Vice President, Global Safety Assessment, where she was responsible for leading the Company's global Safety Assessment organization, and positioning the biness for continued, long term growth and success. In October 2022, Ms. Parisotto was promoted to Corporate Executive Vice President, and assumed the additional oversight of then Discovery Services biness to lead its strategic vision and operational growth, as ll as enhance the synergies beten the binesses and with clients across the global DSA segment. Ms. Parisotto holds a B.S. in Accounting from the University of Nevada, Reno, an M.B.A. from the University of Phoenix, and is a Certified Public Accountant.
- Glenn Coleman
格伦·科尔曼（Glenn Coleman）自2024年以来，科尔曼先生最近一直担任Premier, Inc.公司的首席财务官和首席行政官，该公司是一家10亿美元的TERM1服务提供商。在担任此职务之前，他是两家上市公司的首席财务官，分别是登士柏国际公司和Integra Life Sciences Holdings Corporation。科尔曼先生于2022年至2024年期间担任DENSTPLY的执行副总裁兼首席财务官。在加入DENTSPLY之前，他曾于2014年至2022年在Integra Life Sciences担任运营和财务领导职务，包括2019年至2022年担任执行副总裁兼首席运营官，并担任国际首席财务官和公司副总裁。除了作为CFO监督其财务部门外，作为Integra的COO，Coleman先生领导运营和大部分人才队伍，包括临床、研发、制造和质量职能，同时还领导国际团队。在加入Integra之前，Coleman先生曾在全球领先的制造和电信BINESS任职25年，包括Curtiss Wright Corporation和阿尔卡特朗讯，并在PricewaterhoeCoopers LLP（前身为Coopers & Lybrand）开始其职业生涯。Coleman先生拥有蒙特克莱尔州立大学BINCE Administration理学学士学位，是一名注册会计师。
Glenn Coleman Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1 billion healthcare services biness. Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation. Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024. Prior to DENTSPLY, he held operational and financial leadership positions at Integra Life Sciences from 2014 to 2022, including as Executive Vice President and Chief Operating Officer from 2019 to 2022, and previoly as CFO and Corporate Vice President, International. In addition to overseeing its Finance department as CFO, as Integra's COO, Mr. Coleman led operations and most of its talent force, including clinical, research and development, manufacturing, and quality functions while also leading the international team. Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global manufacturing and telecommunications binesses, including Curtiss Wright Corporation and Alcatel Lucent, and began his career at PricewaterhoeCoopers LLP (formerly Coopers & Lybrand). Mr. Coleman holds a Bachelor of Science degree in Biness Administration from Montclair State University and is a Certified Public Accountant.- 格伦·科尔曼（Glenn Coleman）自2024年以来，科尔曼先生最近一直担任Premier, Inc.公司的首席财务官和首席行政官，该公司是一家10亿美元的TERM1服务提供商。在担任此职务之前，他是两家上市公司的首席财务官，分别是登士柏国际公司和Integra Life Sciences Holdings Corporation。科尔曼先生于2022年至2024年期间担任DENSTPLY的执行副总裁兼首席财务官。在加入DENTSPLY之前，他曾于2014年至2022年在Integra Life Sciences担任运营和财务领导职务，包括2019年至2022年担任执行副总裁兼首席运营官，并担任国际首席财务官和公司副总裁。除了作为CFO监督其财务部门外，作为Integra的COO，Coleman先生领导运营和大部分人才队伍，包括临床、研发、制造和质量职能，同时还领导国际团队。在加入Integra之前，Coleman先生曾在全球领先的制造和电信BINESS任职25年，包括Curtiss Wright Corporation和阿尔卡特朗讯，并在PricewaterhoeCoopers LLP（前身为Coopers & Lybrand）开始其职业生涯。Coleman先生拥有蒙特克莱尔州立大学BINCE Administration理学学士学位，是一名注册会计师。
- Glenn Coleman Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1 billion healthcare services biness. Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation. Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024. Prior to DENTSPLY, he held operational and financial leadership positions at Integra Life Sciences from 2014 to 2022, including as Executive Vice President and Chief Operating Officer from 2019 to 2022, and previoly as CFO and Corporate Vice President, International. In addition to overseeing its Finance department as CFO, as Integra's COO, Mr. Coleman led operations and most of its talent force, including clinical, research and development, manufacturing, and quality functions while also leading the international team. Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global manufacturing and telecommunications binesses, including Curtiss Wright Corporation and Alcatel Lucent, and began his career at PricewaterhoeCoopers LLP (formerly Coopers & Lybrand). Mr. Coleman holds a Bachelor of Science degree in Biness Administration from Montclair State University and is a Certified Public Accountant.
- James C. Foster
James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
James C. Foster joined Charles River Laboratories International, Inc. in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.- James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
- James C. Foster joined Charles River Laboratories International, Inc. in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.
- Michael G. Knell
Michael G. Knell，自2012年3月起，一直担任本公司的财务副总裁兼首席会计官。在加盟本公司之前，他任职于安永会计师事务所波士顿办事处；自1998年起，他担任各种职位，包括最近担任的保证业务合伙人；从2006年直到2011年7月他晋升为合伙人，一直担任高级经理。他在安永会计师事务所的审计经验包括为各种零售、消费产品和制造业的客户提供服务。他是一名马萨诸塞州的注册会计师，并拥有纽约州立大学布法罗分校的工商管理学士学位。
Michael G. Knell has served as the Company's Vice President of Finance and Chief Accounting Officer since March 2012. Prior to joining the Company, Mr. Knell was with Ernst & Young LLP in its Boston office, where since 1998 he served in various roles, including most recently as Partner-Assurance Services and as a senior manager of Assurance Services from 2006 until his promotion to partner in July 2011. Mr. Knell's audit experience at Ernst & Young included service for a variety of clients in the retail, consumer products and manufacturing industries. Mr. Knell is a Certified Public Accountant in Massachusetts and holds a Bachelor of Science degree in Business Administration from the State University of New York at Buffalo.- Michael G. Knell，自2012年3月起，一直担任本公司的财务副总裁兼首席会计官。在加盟本公司之前，他任职于安永会计师事务所波士顿办事处；自1998年起，他担任各种职位，包括最近担任的保证业务合伙人；从2006年直到2011年7月他晋升为合伙人，一直担任高级经理。他在安永会计师事务所的审计经验包括为各种零售、消费产品和制造业的客户提供服务。他是一名马萨诸塞州的注册会计师，并拥有纽约州立大学布法罗分校的工商管理学士学位。
- Michael G. Knell has served as the Company's Vice President of Finance and Chief Accounting Officer since March 2012. Prior to joining the Company, Mr. Knell was with Ernst & Young LLP in its Boston office, where since 1998 he served in various roles, including most recently as Partner-Assurance Services and as a senior manager of Assurance Services from 2006 until his promotion to partner in July 2011. Mr. Knell's audit experience at Ernst & Young included service for a variety of clients in the retail, consumer products and manufacturing industries. Mr. Knell is a Certified Public Accountant in Massachusetts and holds a Bachelor of Science degree in Business Administration from the State University of New York at Buffalo.